Chronic Kidney Failure (End Stage Renal Disease)
Conditions
Interventions
Hemodiafiltration therapy using JMS GC-X01 dialysis machine and hemodiafilter ABH-22PA for 8 weeks.
Sponsors
Kaikoukai Medical Foundation Meiko Kyoritsu Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients on stable maintenance hemodialysis therapy at least one month on a 3 times per a week schedule with not less than 4 hours per a treatment. 2)Patients corresponding to the following at the time of registration - Total protein: 5.0 - 7.0 g/dL - Hematocrit: 28 - 38%. 3)Patients with capable of obtaining blood flow rate >250 mL/min. 4)Patients who are capable to participate in the study as outpatients. 5)Patients capable of understanding the informed consent form. 6)Aged 20 to <80 years at the time of informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients requiring another blood purification therapy such as peritoneal dialysis other than hemodiafiltration within this study period. 2)Patients with a medical history of anaphylaxis symptoms caused by polysulfone or polyvinylpyrrolidone (PVP). 3)Patients with hypoalbuminemia. 4)Female patients who are or have possibility of pregnant, or breast feeding. 5)Patients who have a history of liver, heart, or lung diseases (ex. Decompensated cirrhosis). 6)Patients with previously untreated malignant tumors. 7)Patients with dementia. 8)Patients having a plan of participating in any other clinical trial within this study period. 9)Patients in the opinion of the principal investigator to disqualify from participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of albumin leakage | — |
Countries
Japan
Contacts
Public ContactMasahiro Taoka
Kaikoukai Medical Foundation Meiko Kyoritsu Clinic
Outcome results
None listed